4th Tumor Myeloid Targeting Therapies Summit 2024

Conference themes
The landscape of innate immune cells is rapidly advancing towards clinical applications. Multiple published studies in the last year repeatedly affirm that targeting myeloid cells rather than the cancer cells themselves can shrink tumors, further providing confidence in their potential as a clinically effective therapeutic.

Professional congress organizer (PCO)
Hanson Wade

Notes
Brochure: https://go.evvnt.com/2219781-3?pid=4832

Speakers: Akshata Udyavar, Senior Director, Actym Therapeutics, Peter Ellmark, CSO, Alligator Bioscience, Stephanie Casey Parks, Principal Scientist, Amgen, and more

https://go.evvnt.com/2219781-2?pid=4832

Mr. Luke Kelly